PHP
VKTX icon

Parkman Healthcare Partners’s Viking Therapeutics VKTX Stock Holding History

Parkman Healthcare Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,372
Closed -$1.08M – 104
2024
Q2 		$1.08M Sell
20,372
-9,926
-33% -$651K 0.14% 80
2024
Q1 		$2.48M Buy
+30,298
New +$1.35M 0.3% 80

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Parkman Healthcare Partners's VKTX Position: Q3 2024 in Review

Parkman Healthcare Partners sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 20,372 shares — an estimated $1.08M sold.

Parkman Healthcare Partners first reported a position in VKTX in Q1 2024 and held it in 2 quarters. The position peaked at $2.48M in Q1 2024. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Parkman Healthcare Partners reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 20,372 Viking Therapeutics shares in Q3 2024, an estimated $1.08M.
  • Parkman Healthcare Partners first reported a position in Viking Therapeutics in Q1 2024 and held it in 2 quarters.
  • Parkman Healthcare Partners's Viking Therapeutics position peaked at $2.48M in Q1 2024.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Parkman Healthcare Partners's 13F filing for Q3 2024, filed 14 Nov 2024.